TBPH
Theravance Biopharma Inc
17.00$
+0.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 96.7% | 79.1% | 82.7% | 85.8% | 95.1% | 82.8% | 83.9% | 66.7% | 58.2% | 35.0% | 45.5% | 86.2% | |
| 26.4% | 37.6% | 53.9% | 20.2% | 67.5% | 14.2% | 17.4% | 24.0% | 49.1% | 10.4% | 10.7% | 34.6% | |
| 90.6% | 57.5% | 78.4% | 79.0% | 90.2% | 68.7% | 62.5% | 46.3% | 53.9% | 26.8% | 24.9% | 64.9% | |
| 0.6% | 12.4% | 1.4% | 1.6% | 1.9% | 12.4% | 14.9% | 15.4% | 2.8% | 4.6% | 19.3% | 19.7% | |
| 3.7% | 3.3% | 1.9% | 3.8% | 0.0% | 0.0% | 4.3% | 2.7% | 0.2% | 0.0% | -19.3% | – | |
| 2.9% | 3.3% | 1.3% | 2.3% | 2.4% | 3.1% | 3.5% | 14.2% | 2.0% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 14.2% | 19.0% | 45.2% | 73.9% | 109.2% | 154.8% | 164.8% | 190.3% | 27.3% | 44.2% | 50.4% | 38.9% | |
| 12.2% | 16.5% | 7.7% | 14.2% | 17.6% | 27.3% | 26.3% | 15.6% | 4.7% | 6.5% | 9.1% | 7.9% | |
| 66.0% | 74.3% | 34.8% | 50.7% | – | 4.3% | 6.2% | 4.7% | 1.1% | 1.0% | 3.0% | 2.3% | |
| 2.9% | 6.3% | 0.3% | 1.3% | 1.6% | 1.2% | 1.4% | 0.8% | 0.3% | 0.4% | 0.6% | 0.5% | |
| 0.0% | 0.0% | 34.8% | 50.7% | 81.1% | 108.9% | 48.4% | 159.9% | – | – | – | – | |
| 85.8% | 81.0% | 54.8% | 26.1% | -9.2% | -54.8% | -64.8% | -90.3% | 72.7% | 55.8% | 49.6% | 61.1% | |
| -41.3% | -107.1% | -80.1% | -180.7% | -180.7% | -305.4% | -325.5% | -460.5% | -140.6% | -238.0% | -272.6% | -177.0% | |
| 9.4% | 11.4% | 7.0% | 11.9% | 9.6% | 13.6% | 13.3% | 18.5% | 12.1% | 14.5% | 13.8% | 10.6% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.